SAN FRANCISCO (AP) _ The biotechnology field is littered with the debris of would-be miracle cures. These days, the buzz is building around a technology called ``RNA interference,'' whose legions of ...

The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...

-- Novel approach to gene knockdown uses proprietary CASi (Conditionally Activated siRNA) molecules optimized to “switch” on, activating siRNA therapeutics only in selected cells -- -- CASi platform, ...

A new possibility for managing cardiovascular disease through RNA interference (RNAi) gene therapies. As cardiovascular diseases continue to be the leading cause of death globally, this technology ...

(MENAFN- GlobeNewsWire - Nasdaq) RNA interference (RNAi) therapy offers groundbreaking potential to revolutionize disease treatment by targeting gene silencing. Opportunities lie in developing ...

Through its innovative asymmetric siRNA platforms, OliX Pharmaceuticals is opening up huge opportunities in RNA interference-therapeutic development to address unmet needs for various indications ...

For decades, the central dogma of molecular biology—DNA makes RNA, RNA makes protein, protein makes phenotype—was the guiding framework for understanding inheritance and disease. This model explained ...

KANSAS CITY, Mo.--(BUSINESS WIRE)--TechAccel today announced the launch of RNAissance Ag LLC, a new company that holds the exclusive license to RNA-interference technology in partnership with the ...

Please provide your email address to receive an email when new articles are posted on . ROME — In this Healio Video Perspective from the FLORetina-ICOOR meeting, Bart Leroy, MD, PhD, speaks about RNA ...

LONDON, Feb 26 (Reuters) - Britain's Ark Therapeutics said on Thursday it had filed a patent application for a new genetic technique that represents an advance in so-called RNA interference technology ...

(RTTNews) - Wave Life Sciences (WVE), a clinical-stage biotechnology company, on Thursday initiated the Phase 1 INLIGHT clinical trial for WVE-007, a novel, long-acting RNA-based therapeutic aimed at ...